Clearstead Advisors, LLC Halozyme Therapeutics, Inc. Transaction History
Clearstead Advisors, LLC
- $5.78 Billion
- Q2 2024
A detailed history of Clearstead Advisors, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Clearstead Advisors, LLC holds 429 shares of HALO stock, worth $24,414. This represents 0.0% of its overall portfolio holdings.
Number of Shares
429
Previous 172
149.42%
Holding current value
$24,414
Previous $6,000
266.67%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding HALO
# of Institutions
488Shares Held
122MCall Options Held
208KPut Options Held
66.3K-
Black Rock Inc. New York, NY17.6MShares$1 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$733 Million0.01% of portfolio
-
State Street Corp Boston, MA5.81MShares$331 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.04MShares$230 Million4.92% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.72MShares$212 Million0.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $7.93B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...